Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Item
http://www.wikidata.org/entity/Q36472640
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Belimumab in the management of systemic lupus erythematosus - an update.Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.B Cell-Based Treatments in SLE: Past Experience and Current Directions.Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.When to use belimumab in SLE.Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy.
P2860

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Item
http://www.wikidata.org/entity/Q36472640
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Response to belimumab among pa ...... the OBSErve study in the USA.
@ast
Response to belimumab among pa ...... the OBSErve study in the USA.
@en
type
label
Response to belimumab among pa ...... the OBSErve study in the USA.
@ast
Response to belimumab among pa ...... the OBSErve study in the USA.
@en
prefLabel
Response to belimumab among pa ...... the OBSErve study in the USA.
@ast
Response to belimumab among pa ...... the OBSErve study in the USA.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Response to belimumab among pa ...... m the OBSErve study in the USA
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932